KALA BIO (NASDAQ: KALA) announced a 1-for-50 reverse stock split of its common stock, effective at 4:05 p.m. on May 8, 2026, with split-adjusted trading set to begin on the Nasdaq Capital Market at the open on May 11, 2026. The reverse split will reduce the company’s outstanding common shares from approximately 929.5 million to 18.6 million, with cash payments issued in lieu of fractional shares and proportional adjustments made to outstanding equity awards, warrants and other convertible securities.
This corporate action is a strategic move by KALA BIO to address potential non-compliance with Nasdaq’s minimum bid price requirement, which mandates that listed stocks maintain a closing bid price of at least $1.00 per share. By consolidating shares, the company aims to increase its stock price to a level more attractive to institutional investors and to meet continued listing standards. The reverse split also reflects the company's efforts to stabilize its capital structure as it advances its proprietary biologics pipeline and AI platform-as-a-service business.
KALA BIO is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.
For more information about the company, please visit: https://www.researgency.ai/. To view the full press release, visit https://ibn.fm/yUznR.
